Print
Publish Date : 16-09-2022
Description : “The effort put forth by Agrinnovate India is commendable” said Dr. Himanshu Pathak, Secretary (DARE) & Director General (ICAR) and Chairman, Agrinnovate India Limited (AgIn) during the “ICAR-NRC Equines & ICAR-IVRI Lumpi-ProVacind Technology Transfer” event held on 16th September 2022. Agrinnovate, the commercial arm of ICAR, granted a non-exclusive license to Biovet Pvt. Ltd. Dr. Bhupander Nath Tripathi, Deputy Director General (Animal Science) highlighted the relevance of the technology and said that the vaccine could help the company to start manufacturing as soon as possible so as to make the vaccine market ready for further dissemination to the farmers helping them to overcome the disease. Dr. Sudha Mysore, CEO, Agrinnovate India Ltd. indicated that this technology transfer is a major game changer for AgIn, with this transfer AgIn’s gross turnover reaches Rs. 17 crores Since 2018-19. Dr. Yash Pal, Director, ICAR-NRCE outlined the technical results of the technology Lumpi-ProVacind. & field results are encouraging and Dr. Triveni Dutt, Director, ICAR-IVRI expressed gratitude to the council for timely support. Dr. Sreenivasulu Kilari, Executive Director, Biovet Pvt. Ltd. mentioned that the organization is glad to avail the license for Lumpi-ProVacind and expressed that experience with Agrinnovate in the technology transfer process exceptional. Dr. Himanshu Pathak congratulated the Biovet Pvt. Ltd., ICAR-NRCE, ICAR-IVRI and AgIn for the successful transfer of the technology. He further elaborated this technology will defiantly meet out the standard of the market and significantly provide a defence mechanism to control the devastating lumpy skin disease. Lumpi-ProVacind is safe in animals and induces LSDV-specific antibody-and cell-mediated immune response, besides providing complete protection against lethal LSDV challenge. Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease. The immunity induced by homologous live-attenuated LSD vaccines usually persists for a minimum period of 1 year. A single dose of the vaccine contains 103.5 TCID50 of live-attenuated LSDV (Ranchi strain). The vaccine is stored at 4°C. The vaccine must be shipped on ice and must be used within a few hours after reconstitution. The patent has been filed for the technology.
Agrinnovate India Limited (AgIn) grants “Non-Exclusive Rights” to Biovet Pvt. Ltd. for Commercial production of “Lumpi-ProVacind” jointly developed by ICAR-NRC Equines and ICAR-IVRI
Publish Date : 16-09-2022
Description : “The effort put forth by Agrinnovate India is commendable” said Dr. Himanshu Pathak, Secretary (DARE) & Director General (ICAR) and Chairman, Agrinnovate India Limited (AgIn) during the “ICAR-NRC Equines & ICAR-IVRI Lumpi-ProVacind Technology Transfer” event held on 16th September 2022. Agrinnovate, the commercial arm of ICAR, granted a non-exclusive license to Biovet Pvt. Ltd. Dr. Bhupander Nath Tripathi, Deputy Director General (Animal Science) highlighted the relevance of the technology and said that the vaccine could help the company to start manufacturing as soon as possible so as to make the vaccine market ready for further dissemination to the farmers helping them to overcome the disease. Dr. Sudha Mysore, CEO, Agrinnovate India Ltd. indicated that this technology transfer is a major game changer for AgIn, with this transfer AgIn’s gross turnover reaches Rs. 17 crores Since 2018-19. Dr. Yash Pal, Director, ICAR-NRCE outlined the technical results of the technology Lumpi-ProVacind. & field results are encouraging and Dr. Triveni Dutt, Director, ICAR-IVRI expressed gratitude to the council for timely support. Dr. Sreenivasulu Kilari, Executive Director, Biovet Pvt. Ltd. mentioned that the organization is glad to avail the license for Lumpi-ProVacind and expressed that experience with Agrinnovate in the technology transfer process exceptional. Dr. Himanshu Pathak congratulated the Biovet Pvt. Ltd., ICAR-NRCE, ICAR-IVRI and AgIn for the successful transfer of the technology. He further elaborated this technology will defiantly meet out the standard of the market and significantly provide a defence mechanism to control the devastating lumpy skin disease. Lumpi-ProVacind is safe in animals and induces LSDV-specific antibody-and cell-mediated immune response, besides providing complete protection against lethal LSDV challenge. Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease. The immunity induced by homologous live-attenuated LSD vaccines usually persists for a minimum period of 1 year. A single dose of the vaccine contains 103.5 TCID50 of live-attenuated LSDV (Ranchi strain). The vaccine is stored at 4°C. The vaccine must be shipped on ice and must be used within a few hours after reconstitution. The patent has been filed for the technology.